3F3W
Drug resistant cSrc kinase domain in complex with inhibitor RL45 (Type II)
Summary for 3F3W
| Entry DOI | 10.2210/pdb3f3w/pdb |
| Related | 2QI8 2QLQ 2QQ7 3F3T 3F3U 3F3V |
| Descriptor | Proto-oncogene tyrosine-protein kinase Src, 1-{4-[(6-aminoquinazolin-4-yl)amino]phenyl}-3-[3-tert-butyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]urea (3 entities in total) |
| Functional Keywords | allosteric, type ii, dfg-out, drug resistance mutation, alternative splicing, atp-binding, kinase, lipoprotein, myristate, nucleotide-binding, phosphoprotein, proto-oncogene, sh2 domain, sh3 domain, transferase, tyrosine-protein kinase |
| Biological source | Gallus gallus (Chicken) |
| Cellular location | Cell membrane (By similarity): P00523 |
| Total number of polymer chains | 2 |
| Total formula weight | 66558.81 |
| Authors | Grutter, C.,Kluter, S.,Getlik, M.,Rauh, D. (deposition date: 2008-10-31, release date: 2009-06-02, Last modification date: 2023-11-01) |
| Primary citation | Getlik, M.,Grutter, C.,Simard, J.R.,Kluter, S.,Rabiller, M.,Rode, H.B.,Robubi, A.,Rauh, D. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc J.Med.Chem., 52:3915-3926, 2009 Cited by PubMed Abstract: The emergence of drug resistance remains a fundamental challenge in the development of kinase inhibitors that are effective over long-term treatments. Allosteric inhibitors that bind to sites lying outside the highly conserved ATP pocket are thought to be more selective than ATP-competitive inhibitors and may circumvent some mechanisms of drug resistance. Crystal structures of type I and allosteric type III inhibitors in complex with the tyrosine kinase cSrc allowed us to employ principles of structure-based design to develop these scaffolds into potent type II kinase inhibitors. One of these compounds, 3c (RL46), disrupts FAK-mediated focal adhesions in cancer cells via direct inhibition of cSrc. Details gleaned from crystal structures revealed a key feature of a subset of these compounds, a surprising flexibility in the vicinity of the gatekeeper residue that allows these compounds to overcome a dasatinib-resistant gatekeeper mutation emerging in cSrc. PubMed: 19462975DOI: 10.1021/jm9002928 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.6 Å) |
Structure validation
Download full validation report
